Breaking Finance News

Zymeworks (NYSE:ZYME) target price raised to $20.00, reported today by Barclays Capital

Stating a potential upside of 0.52%, Barclays Capital upped the price target of Zymeworks (NYSE:ZYME) to $20.00

Yesterday Zymeworks (NYSE:ZYME) traded -6.89% lower at $13.14. The company’s 50-day moving average is $7.47 and its 200-day moving average is $9.28. The last stock close price is up -16.99% from the 200-day moving average, compared to the S&P 500 which has increased 0.01% over the same time. 29,565 shares of the stock were exchanged, up from an average trading volume of 23,725

See Chart Below

Zymeworks (NYSE:ZYME)

Zymeworks has a 52 week low of $6.25 and a 52 week high of $14.25 The company’s market cap is currently $0.

General Information About Zymeworks (NYSE:ZYME)

Zymeworks Inc is a Canada-based clinical-stage biopharmaceutical company. The Company focuses on the discovery, development and commercialization of multifunctional biotherapeutics. The Company's ZymeCAD platform is for protein modeling and structure-guided protein engineering. The Company's platforms include Azymetric Platform, AlbuCORE Platform, EFECT Platform and Zymelink Conjugation Platform + Cytotoxins. The Company's lead product candidate, ZW25, is a bispecific antibody, which is being evaluated in an adaptive Phase I clinical trial. Its ZW33 is a bi-specific antibody that delivers a cytotoxic payload to cancers cells by binding to different epitopes (bi-paratopic targeting) of the overexpressed HER2 protein. It focuses on developing a pipeline of preclinical product candidates and discovery-stage programs in immuno-oncology and other therapeutic areas. It analyzes protein characteristics to develop the scope of protein engineering to tackle biological systems.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.